BOOM
Recent additions may not be included but will usually appear in 24 hrs or less.
| Rational | Source |
|---|---|
|
Potential Probiotic or Trigger of Gut Inflammation - The Janus-Faced Nature of Cannabidiol-Rich Cannabis Extract. ✅
Go to Publication ✅
Journal of dietary supplements (J Diet Suppl ) Vol: 17 Issue 5 Pages: 543-560 Pub: 2020 Epub: 2020 May 13 Authors Skinner CM , Nookaew I , Ewing LE , Wongsurawat T , Jenjaroenpun P , Quick CM , Yee EU , Piccolo BD , ElSohly M , Walker LA , Gurley B , Koturbash I , |
|
|
Potential Probiotic or Trigger of Gut Inflammation - The Janus-Faced Nature of Cannabidiol-Rich Cannabis Extract. ✅
Go to Publication ✅
Journal of dietary supplements (J Diet Suppl ) Vol: 17 Issue 5 Pages: 543-560 Pub: 2020 Epub: 2020 May 13 Authors Skinner CM , Nookaew I , Ewing LE , Wongsurawat T , Jenjaroenpun P , Quick CM , Yee EU , Piccolo BD , ElSohly M , Walker LA , Gurley B , Koturbash I , |
|
|
Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome. ✅
Go to Publication ✅
Brain, behavior, and immunity (Brain Behav Immun ) Vol: 82 Issue Pages: 25-35 Pub: 2019 Nov Epub: 2019 Jul 26 Authors Al-Ghezi ZZ , Busbee PB , Alghetaa H , Nagarkatti PS , Nagarkatti M , |
|
|
Integrating fecal metabolomics and intestinal microbiota to study the mechanism of cannabidiol in the treatment of idiopathic pulmonary fibrosis. ✅
Go to Publication ✅
Frontiers in pharmacology (Front Pharmacol ) Vol: 15 Issue Pages: 1358626 Pub: 2024 Epub: 2024 Feb 6 Authors Sun M , Zhang F , Lu F , Yu D , Wang Y , Chen P , Liu S , |
|
|
Integrating fecal metabolomics and intestinal microbiota to study the mechanism of cannabidiol in the treatment of idiopathic pulmonary fibrosis. ✅
Go to Publication ✅
Frontiers in pharmacology (Front Pharmacol ) Vol: 15 Issue Pages: 1358626 Pub: 2024 Epub: 2024 Feb 6 Authors Sun M , Zhang F , Lu F , Yu D , Wang Y , Chen P , Liu S , |
|
|
Integrating fecal metabolomics and intestinal microbiota to study the mechanism of cannabidiol in the treatment of idiopathic pulmonary fibrosis. ✅
Go to Publication ✅
Frontiers in pharmacology (Front Pharmacol ) Vol: 15 Issue Pages: 1358626 Pub: 2024 Epub: 2024 Feb 6 Authors Sun M , Zhang F , Lu F , Yu D , Wang Y , Chen P , Liu S , |
|
|
Integrating fecal metabolomics and intestinal microbiota to study the mechanism of cannabidiol in the treatment of idiopathic pulmonary fibrosis. ✅
Go to Publication ✅
Frontiers in pharmacology (Front Pharmacol ) Vol: 15 Issue Pages: 1358626 Pub: 2024 Epub: 2024 Feb 6 Authors Sun M , Zhang F , Lu F , Yu D , Wang Y , Chen P , Liu S , |
|
|
The Potential Antinociceptive Effect and Mechanism of Cannabis sativa L. Extract on Paclitaxel-Induced Neuropathic Pain in Rats Uncovered by Multi-Omics Analysis. ✅
Go to Publication ✅
Molecules (Basel, Switzerland) (Molecules ) Vol: 29 Issue 9 Pages: Pub: 2024 Apr 25 Epub: 2024 Apr 25 Authors Xu Y , Yao L , Guo Y , Shi C , Zhou J , Hua M , |
BOOM
All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.
Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance. Special thanks to Oliver Luk, B.Sc. (Biology) from BiomeSight for spot checking the coding of data from the US National Library of Medicine
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.
